Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Fellowship - Priority Announcement: Gastroenterology

University of Calgary

$67,500.00

Protease-activated receptor (PAR)-2: A novel effector of mucosal healing in inflammatory bowel diseases.

FY 2019-20

Summary
The inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are chronic, relapsing and remitting diseases affecting ~250,000 Canadians. The cause of IBD is unknown and current drug therapies are often ineffective, have serious side effects or are very expensive. The intestinal lining (called the epithelium) is damaged in IBD and the process of epithelial healing is key to the resolution of disease to prevent activation of the gut's immune system by bacteria and other constituents of the gut lumen. We contend that targeting this epithelial repair process represents a novel therapeutic adjunct to drugs that target the immune system. In particular, we need to understand the cellular mechanisms triggered by inflammation that activate repair pathways to drive re-epithelialization during mucosal healing. During inflammation, there is an increase in proteases (enzymes that degrade proteins) within the lamina propria, and these would come in contact with the surface of epithelial cells. These cells express a unique class of receptor, called protease-activated receptors (PARs) could provide a means by which proteases could alter epithelial behaviour. The MacNaughton lab has generated preliminary data to support the hypothesis that activation of one if these PARs, PAR2, drives a pro-healing program in the injured or inflamed epithelium, and that this program is critical to the healing process. Testing this hypothesis will be the theme of my work in the MacNaughton lab and has the potential to uncover new pathways that could be the targets for novel therapeutic approaches to IBD. We will use a new technique whereby we can grow "mini-guts" from pieces of tissue obtained from consenting patients during colonoscopy. In the lab, we can injury these mini-guts and then test to see if activation of PAR2 enhances healing. A further aim of the project will be to determine the cellular processes that mediate this effect.
Program
Fellowship - Priority Announcement: Gastroenterology
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
417579
Name
Périco Larissa L
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario); Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Protease-activated receptor (PAR)-2: A novel effector of mucosal healing in inflammatory bowel diseases.
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$67,500
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Gastroenterology
Keyworddelim
Cell Migration; Cell Signaling; Colitis; Epithelium; Mucosal Healing; Organoids; Protease-Activated Receptors (Pars)
Abstract
The inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are chronic, relapsing and remitting diseases affecting ~250,000 Canadians. The cause of IBD is unknown and current drug therapies are often ineffective, have serious side effects or are very expensive. The intestinal lining (called the epithelium) is damaged in IBD and the process of epithelial healing is key to the resolution of disease to prevent activation of the gut's immune system by bacteria and other constituents of the gut lumen. We contend that targeting this epithelial repair process represents a novel therapeutic adjunct to drugs that target the immune system. In particular, we need to understand the cellular mechanisms triggered by inflammation that activate repair pathways to drive re-epithelialization during mucosal healing. During inflammation, there is an increase in proteases (enzymes that degrade proteins) within the lamina propria, and these would come in contact with the surface of epithelial cells. These cells express a unique class of receptor, called protease-activated receptors (PARs) could provide a means by which proteases could alter epithelial behaviour. The MacNaughton lab has generated preliminary data to support the hypothesis that activation of one if these PARs, PAR2, drives a pro-healing program in the injured or inflamed epithelium, and that this program is critical to the healing process. Testing this hypothesis will be the theme of my work in the MacNaughton lab and has the potential to uncover new pathways that could be the targets for novel therapeutic approaches to IBD. We will use a new technique whereby we can grow "mini-guts" from pieces of tissue obtained from consenting patients during colonoscopy. In the lab, we can injury these mini-guts and then test to see if activation of PAR2 enhances healing. A further aim of the project will be to determine the cellular processes that mediate this effect.
Competitiondate
201910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Périco, Larissa L
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $67,500~ $0~
University of Calgary - $67,500 Grant (2019-20) | Canada Spends